Nephrotoxicity in cancer treatment: An overview.

Core tip: Nephrotoxicity is an adverse event that is well described with the use of conventional cytotoxic agents and with the advent of new agents directed to specific genes/proteins in recent decades. Its nephrotoxic potential has also been observed, which limits the effectiveness of treatment and increases the morbidity and mortality of these patients. Our objective was to recognize the main chemotherapeutic drugs with nephrotoxic potential and the most common types of kidney injury to prevent or at least reduce their occurrence and severity, allowing better therapeutic indices.

INTRODUCTION

Cancer is an important cause of death worldwide and is associated with significant morbidity related to the underlying disease itself, as well as the adverse effects of chemotherapy. Conventional chemotherapeutic drugs are first-line agents to treat several malignancies but cause kidney toxicity, which occurs when kidney excretion properly due to the action of harmful chemicals[ 1 ]. In the last several decades, novel cancer drugs have been developed and used in clinical practice, being more specific against cancer cells and extremely effective against several previously untreatable malignancies, the so-called molecularly targeted agents, but also suffer from nephrotoxicity (Figure 1 ), which limits the efficacy of the treatment and impact their quality of life and overall survival[ 2 ]. A variety of renal complications can occur among cancer patients associated with malignancy (paraneoplastic renal manifestation, need for nephrectomy and urinary tract obstruction) or its treatment (nephrotoxicity effects of chemotherapy: Acute kidney disease (AKI), due to toxic acute tubular necrosis, thrombotic microangiopathy (TMA), and crystal nephropathy; proteinuria/nephrotic syndrome due to TMA and glomerulopathies; tubulopathies due to electrolyte and acid-base disorders; and chronic kidney disease (CKD) due to glomerulopathies or interstitial nephritis) or intrinsic kidney injury related to other pre-existing patient risk factors such as female gender, reduced muscle mass and reduced body water - mainly related to higher age, hypertension, diabetes, congestive heart failure, cirrhosis, hepatic failure, hyperbilirubinemia and hypoalbuminemia. Regarding kidney-related risk factors, are listed nephrosis, previous kidney injury, nephrotic syndrome and hydroelectrolytic disturbance which can be consequence of vomiting, diarrhea and use of diuretics[ 3 ]. Kidney injury in cancer patients is shown in Figure 2 .

Many of the drug-related nephrotoxicities do not have a well-defined mechanism of injury or pathophysiology, which makes it difficult to develop strategies to prevent or minimize their occurrence. However, there are some factors that may contribute to the higher incidence of this adverse event including intravascular volume depletion, the associated use of non-chemotherapeutic nephrotoxic drugs (analgesics, antibiotics, proton pump inhibitors and bone-targeted therapies), radiographic ionic contrast media or radiation therapy, urinary tract obstruction, and intrinsic renal disease[ 4 ]. These factors should be considered by the oncologist before initiating treatment to minimize the risk of nephrotoxicity. Table 1 summarizes the main classes of chemotherapy and their representatives, the renal lesions associated with its use, and the mechanism that leads to nephrotoxicity. This review provides an update of anticancer drugs that are associated with kidney injury.

CONVENTIONAL CYTOTOXIC AGENTS

Alkylating agents

Bendamustine is a potent cytotoxic agent that is approved for use in the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin’s lymphoma[ 5 ]. In only one study, the relationship of this drug to induction of AKI was observed[ 6 ]. Cyclophosphamide has toxicity caused by some of its metabolites, mainly in bone marrow and gonads, and its use has been related to the development of bladder cancer. Hemorrhagic cystitis is the major adverse urological effect, and its severity is related to dose dependence and treatment duration[ 7 ]. Cyclophosphamide-induced nephrotoxicity is often not considered in clinical practice, as the change in creatinine levels is of little significance[ 8 ]. However, a histological study of cyclophosphamide-treated mice found a significant inflammatory lesion in the animals' renal tissue. This injury has been attributed to increased oxidative stress on renal cells and decreased antioxidant agents[ 9 ]. This agent has been associated with the development of syndrome of inappropriate antidiuretic hormone secretion (SIADH), leading to severe hyponatremia in patients receiving high or moderate intravenous doses of this drug[ 10 ]. Nephrotoxic effects of ifosfamide are most commonly reported in childhood. In one study, insufficiency renal was observed in more than 80% of patients. In addition, a higher prevalence of Fanconi’s syndrome with hypophosphatemia, hypokalemia, glycosuria, and proteinuria is well documented[ 11 , 12 ]. Melphalan is generally used to treat multiple myeloma and ovarian cancer[ 13 ]. The association of high-dose melphalan use with SIADH has been reported[ 14 ]. In prolonged therapy with nitrosoureas, a slow, progressive, chronic, and often irreversible interstitial nephritis can be observed. However, the nephrotoxic mechanism of this class is not well understood in the literature[ 15 ]. Streptozotocin, which is used in several studies to induce diabetes in animal study models, causes mild proteinuria and elevated serum creatinine levels, followed by significant tubular damage that results in phosphaturia, glycosuria and uricosuria[ 16 , 17 ]. Trabectedin is a marine-derived alkylating agent that is used to treat advanced soft tissue sarcoma and has reports of renal failure, some of which have been attributed to rhabdomyolysis[ 18 , 19 ].

Antimetabolites

Clofarabine is approved for the treatment of acute lymphoblastic leukemia in children, as well as acute myeloid leukemia and acute lymphoblastic leukemia in adults. Two reports of severe kidney injury have been documented following administration of this drug as proteinuria and anuria requiring dialysis[ 20 , 21 ]. Renal insufficiency has been reported in some patients that undergone allogeneic hematopoietic cell transplantation[ 22 , 23 ]. Methotrexate is one of the most widely used antineoplastic drugs. Treatment with high doses may lead to acute kidney injury due to crystal precipitation in the tubules and induction of tubular injury[ 24 ]. This drug may transiently decrease the glomerular filtration rate (GFR) due to an afferent arteriolar constriction[ 25 ]. Pemetrexed is a methotrexate derivative used to treat advanced non-small cell lung cancer, and its nephrotoxic effects include acute tubular necrosis, interstitial edema, tubular acidosis, and diabetes insipidus[ 26 - 28 ]. Gemcitabine is used in many advanced neoplasms, being associated with a kidney injury such as hypertension and TMA in a case series. Moreover, hemolytic uremic syndrome may be a potential adverse effect[ 29 ]. Pentostatin is effective in treating hairy cell leukemia, and its use has been associated with mild renal dysfunction in some patients[ 30 ].

Antimicrotubule agents

Paclitaxel is a microtubule inhibitor that is used in various antineoplastic treatments. Its nephrotoxicity was observed in a histological study with mice, in which dose-dependent cellular apoptosis and parenchymal necrosis were reported[ 31 ]. Other antimicrotubule agents, vincristine, vinblastine, and vinorelbine are related to a small number of SIADH cases[ 32 , 33 ].

Antitumor antibiotics

Anthracyclines such as daunorubicin and doxorubicin cause nephrotic syndrome with significant renal lesions and focal segmental glomerular sclerosis. Pegylated liposomal doxorubicin has been linked to renal TMA and AKI[ 34 , 35 ]. Mitomycin nephrotoxicity is well documented due to direct damage to the renal parenchyma[ 36 ]. There are numerous cases reported in the literature of hemolytic uremic syndrome related to the cumulative dose of this drug. This syndrome leads, in most cases, to a slowly progressive renal failure and hypertension[ 37 , 38 ].

Platinum agents

Cisplatin is one of the most widely used agents in cancer treatment and is known as one of the most nephrotoxic drugs. This nephrotoxic effect is dose-dependent and can be reversed with discontinuation of the drug[ 39 ]. The most common findings of renal damage in individuals using cisplatin are AKI, hypomagnesemia, proximal tubular dysfunction, and TMA[ 40 ]. Hydration and dose adjustment in patients with preexisting renal impairment is important to prevent cisplatin-induced nephrotoxicity[ 40 , 41 ]. Standardization of what is recommended is still necessary, mainly because current guidelines follow empirical treatments rather than clinical trials results[ 42 ]. However, this reasoning still depends much more on clinical manifestations and professional practice than isolated laboratory findings[ 41 ].

Another important platinum agent is carboplatin, which has a similar effect to cisplatin but with a significant reduction in expected adverse effects. The main one is hypomagnesemia, which is still less important than expected with cisplatin[ 42 , 43 ]. One caution that should be exercised is for patients who have already taken cisplatin and switched to carboplatin, because although it is not related to AKI, the patient is still at risk for this complication due to contact with cisplatin[ 44 ].

Among the new platinum agents, the third generation is mainly represented by oxaliplatin, a recent agent that has few adverse effects over previous ones and has relevant safety in patients with preexisting renal impairment, and does not require dose adjustment for these patients[ 45 , 46 ].

Other cytotoxic agents

Arsenic trioxide is one of the main cytotoxic agents used in cancer treatments. At low doses commonly used, nephrotoxic effects are not common, which are usually represented by tubulointerstitial disease of the kidney and rhabdomyolysis[ 47 ]. However, because its metabolism is mainly renal, it is important to be careful and closely monitor its use in patients with preexisting renal impairment[ 48 ].

Etoposide is another cytotoxic agent and its use is related to renal insufficiency[ 49 ]. Some guidelines attempt to standardize etoposide’s dose adjustment in patients with renal dysfunction, and although data are different between societies, there is consensus on dose reduction in these patients, as well as discontinuation of their use for lower creatinine clearance[ 42 , 50 ].

Finally, there are also in this group irinotecan and topotecan. The former has hepatic metabolism and poor renal excretion[ 51 ]. Although lower renal complications are therefore expected, there are reports of toxicity in patients with preexisting renal impairment even at low doses[ 52 ]. There is also no standardization regarding its use in these patients. Topotecan is predominantly cleared by the kidneys, and increased toxicity may be seen in patients with moderate renal insufficiency[ 50 , 53 ]. There is still no worldwide consensus on dose adjustment for its use, although some studies are already moving towards standardization of drug dose reduction in patients with renal dysfunction.

Immunomodulatory drugs

This group of antineoplastic drugs is especially important for the treatment of multiple myeloma. Among them, thalidomide stands out first. Studies have shown that there is no relationship between AKI and the use of thalidomide, but the progression of the underlying disease itself. However, some case reports have shown hyperkalemia, requiring no dose adjustment, but close observation of potassium levels[ 54 , 55 ]. Lenalidomide, a thalidomide analog, mainly undergoes renal metabolism, which puts patients with prior renal injury at risk when exposed to this type of treatment and therefore requires dose adjustment[ 56 , 57 ]. Among the findings, AKI was reported including severe renal dysfunction and dialysis necessity[ 58 - 60 ].

Pomalidomide, although its metabolism is mainly hepatic, was related to AKI and nephrolithiasis. However, there are no standardizations for dose adjustment, except for patients on hemodialysis[ 61 , 62 ].

Proteasome inhibitors

Proteasome inhibitors are primarily used for the treatment of multiple myeloma, and the drug Bortezomib has reports of TMA and acute interstitial nephritis with granuloma formation[ 63 ]. However, there are no standardizations regarding drug dose adjustment for patients with renal dysfunction. Carfilzomib, another drug of this class, has reports of TMA and AKI in several studies, such as Siegel et al[ 64 ] and Hájek et al[ 65 ]. The main mechanisms of action are described in Table 1 [ 66 , 67 ]. Despite these data, there is still no standardization for dose adjustments for patients with renal injury. Another representative is ixazomib, which has reports of TMA development, since its excretion is primarily renal[ 68 ]. Thus, guidelines already indicate dose adjustment for patients with renal dysfunction.

MOLECULARLY TARGETED AGENTS

Epidermal growth factor receptor pathway inhibitors

Activation of epidermal growth factor receptor (EGFR) results in phosphorylation of the receptor tyrosine kinase, triggering signaling pathways that modulate cell differentiation, proliferation, and survival[ 69 ]. Such a receptor is a crucial target for the treatment of some cancers such as non-small cell lung cancer, which can be performed by administrating EGFR-tyrosine kinase inhibitors (EGFR-TKIs) or anti-EGFR monoclonal antibodies[ 70 , 71 ].

Rare cases of nephrotic syndrome accompanied by minimal-change disease and membranous nephropathy have been related to the use of gefitinib, an EGFR-TKI[ 72 - 74 ]. Moreover, this drug family might also cause hypomagnesemia, hypophosphatemia, and hypokalemia[ 75 ]. On the other hand, increased renal magnesium loss is associated with the administration of anti-EGFR monoclonal antibodies (cetuximab and panitumumab). That electrolyte wasting leads to hypomagnesemia in up to 37% of patients, which resolves with therapy discontinuation[ 76 , 77 ]. In addition, cetuximab causes hypokalemia in about 8% of treated individuals[ 78 ]. Furthermore, this drug is linked to other very rare complications such as acute kidney injury, nephrotic syndrome, and proliferative glomerulonephritis[ 75 , 79 ].

Human epidermal growth factor receptor 2 inhibitors

Some molecularly targeted therapies aim to inhibit human epidermal growth factor receptor 2 (HER-2), an overexpressed receptor in some breast and gastric /gastroesophageal junction cancers[ 80 - 82 ]. Trastuzumab is the precursor and the most successful example among antibodies aiming HER-2 antagonism[ 83 ]. However, this drug, as well as pertuzumab (a humanized monoclonal antibody), have been implicated in the occurrence of renal impairment, exemplified by acute kidney injury, proteinuria, elevated serum creatinine, and nephritis. In addition, hypertension, hypokalemia, hyponatremia, and hypomagnesemia have also been reported[ 75 ]. The administration of lapatinib, a TKI, has been associated with the development of acute kidney injury and hypokalemia. In a few patients, hyponatremia, hypomagnesemia, and hypertension have also been observed[ 75 , 84 ].

B-cell lymphoma-2 inhibitors

The cell intrinsic apoptotic pathway has B-cell leukemia/lymphoma-2 (BCL-2) proteins as crucial regulators. When such a pathway is disturbed, the improper perpetuation of malignant cells can occur[ 85 ]. Given the context, the emergence of venetoclax, a BCL-2 inhibitor, represents a promising solution for the treatment of refractory chronic lymphocytic leukemia. Despite the benefits, such a drug has been associated with significant incidence of tumor lysis syndrome, leading to huge electrolyte disturbances and AKI. To prevent these effects, the gradual escalation of drug dose administration to the patient is recommended[ 86 , 87 ].

Anaplastic lymphoma kinase inhibitors

Anaplastic lymphoma kinase 1 (ALK-1) belongs to the insulin receptor tyrosine kinase family, which plays an important role in cell growth regulation[ 88 ]. Mutations involving the gene that encodes this kinase are related to malignancies such as anaplastic large cell lymphoma, Hodgkin lymphoma, non-small cell lung cancer, neuroblastoma, and rhabdomyosarcoma[ 89 - 92 ]. Crizotinib is the first-developed ALK inhibitor and has been widely used for the treatment of advanced non-small cell lung cancer with positivity for the ALK fusion gene. Reductions in GFR have been observed in patients who underwent this therapy. However, the premature emergence of this involvement, its negligible cumulative effect, and the quick reversibility after drug discontinuation indicate that the occurrence of this phenomenon is not due to direct nephrotoxicity from crizotinib[ 93 ]. Moreover, this drug is also related to the emergence of complex renal cysts, hyponatremia, and hypokalemia in a limited number of patients; however, all of these are reversible with therapy interruption[ 94 , 95 ].

BRAF inhibitors

BRAF is the encoding gene of a human protein called B-Raf, and if muted, can promote cell proliferation and carcinogenesis[ 96 ]. Molecularly targeted therapies aimed toward its inhibition have been used in individuals with malignant melanoma containing the BRAF V600E mutation[ 97 ]. Vemurafenib is one of the approved drugs for such patients, being related to a reduction in creatinine clearance (reversible with treatment discontinuation) as well as rare cases of AKI, which are more commonly observed in men[ 98 , 99 ]. At a lower frequency, the use of another BRAF inhibitor named dabrafenib can also lead to AKI[ 99 ].

Mammalian target of rapamycin inhibitors

A serine/threonine kinase called mammalian target of rapamycin (mTOR) participates in the signaling pathways of growth factors and cytokines related to oncogenic activity, and its inhibition leads to cell cycle arrest[ 100 ]. The administration of mTOR inhibitors, such as temsirolimus, is associated with the development of proteinuria, and in some cases, has kidney dysfunction as a consequence[ 101 ].

BCR-ABL1 and KIT inhibitors

The t(9;22)(q34;q11) chromosomal translocation that originates from the Philadelphia chromosome results in a BCR-ABL1 gene rearrangement observed in patients with chronic myeloid leukemia (CML)[ 102 , 103 ]. ABL can be targeted by bosutinib, which is used in the treatment of refractory CML and can lead to hypophosphatemia, as well as to a reversible decrease in GFR. With the goal of preventing advanced kidney disturbances due to adverse events from bosutinib, monitoring of renal function is recommended at baseline as well as while the patient undergoes this treatment. Moreover, dose reduction should be conducted when renal impairment due to the therapy occurs[ 104 ]. Besides BCR-ABL1 inhibition, a TKI named desatinib also acts to restrain the platelet-derived growth factor receptor and tyrosine kinase receptor KIT (CD117). This drug is rarely associated with AKI and proteinuria[ 105 , 106 ]. Another BCR-ABL1 and KIT inhibitor, imatinib, can be applied for the treatment of gastrointestinal stromal tumors beyond CML. If used for a long period, such an agent can lead to AKI and CKD, and kidney injury seems to be dose-dependent, with higher doses associated with a higher risk of renal impairment[ 107 , 108 ]. Moreover, imatinib administration is related to the occurrence of hypophosphatemia[ 109 ].

Vascular endothelial growth factor pathway inhibitors

Vascular endothelial growth factor (VEGF) is an essential growth factor that plays a key role in angiogenesis during embryogenesis, wound healing, and tumor growth. It was first investigated as a potential anticancer agent over the past few decades[ 110 ].

There are two types of VEGF pathway inhibitors: VEGF ligand inhibitors, which are antagonists of the VEGF receptor and are represented by ramucirumab, bevacizumab, and aflibercept; and small molecule TKIs (ponatinib, sunitinib, regorafenib, sorafenib, cabozantinib, pazopanib, axitinib, vandetanib, cabozantinib, lenvatinib), which prevent the activation of the VEGF receptor intracellular domain[ 111 ].

In normal conditions, VEGF is produced by the podocytes and binds to its receptors found in glomerular and peritubular endothelium, as well as in mesangial cells. This process maintains the structure of the glomerular basement membrane and the proper glomerular functioning[ 112 ]. Therefore, all drugs that block the VEGF pathway may induce renal abnormalities. Their renal toxicity is mainly renovascular in nature including hypertension and proteinuria, occasionally causing nephrotic syndrome, decreased GFR, and TMA which remains rare[ 113 ]. However, the exact mechanism underlying proteinuria and the factors associated with the occurrence and severity of proteinuria are unknown. It is suggested that preexisting renal disease (including higher baseline urine protein levels and hypertension) and renal cell carcinoma, may be predisposing factors to proteinuria[ 114 , 115 ].

Interruption of anti-VEGF drugs use improves kidney dysfunction, but persistent proteinuria is not unusual. Although angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may lower intraglomerular pressure and diminish protein excretion, no recommendation for use of these agents can be made as there are no controlled studies on the subject[ 116 ].

Although there is a lack of information regarding kidney biopsies in patients that undergo VEGF-targeted agents treatment, studies have demonstrated the presence of collapsing glomerulopathy, TMA, and isolated reports of immune complex glomerulonephritis and cryoglobulinemic[ 117 ]. The most common causative agent is bevacizumab. Less common histologic findings have been reported with bevacizumab such as nephritic syndrome and AKI[ 118 ].

Regarding TKIs, proteinuria and hypertension can be seen with their use. In addition, AKI and diabetes insipidus have been reported in clinical trials of vandetanib, although causality has not been proven. Decreased GFR during therapy has been reported with axitinib, sunitinib, and sorafenib, although renal failure is rare. Patients treated with lenvatinib may progress to renal failure or impairment, while regorafenib has been associated with several electrolyte abnormalities, including hypophosphatemia, hypocalcemia, hyponatremia, and hypokalemia[ 119 , 120 ]. Sorafenib and sunitinib have been associated with acute and chronic interstitial nephritis in case reports[ 121 , 122 ]. Sorafenib is also known to cause hypophosphatemia and hypocalcemia[ 123 ].

Inhibitor of Burton’s tyrosine kinase

Ibrutinib is an irreversible inhibitor of Burton's tyrosine kinase. This drug has activity in B cell malignancies and is approved for the patients with mantle cell lymphoma or chronic lymphocytic leukemia. It may be related to AKI and the mechanism of this injury is unclear, but tumor lysis syndrome might be contributory[ 124 ].

Anti-CD22 immunotoxin

Moxetumomab pasudotox is used to ameliorate the prognosis of patients with relapsing or refractory hairy cell leukemia. Such a drug can be associated with AKI and proteinuria[ 125 ].

Poly-adenosine diphosphate ribose polymerase inhibitors

Inhibitors of poly-adenosine diphosphate ribose polymerase are approved for treatment of BRCA-mutated breast cancer and for platinum-sensitive relapsed epithelial ovarian cancer. Increased creatinine have been reported in some patients treated with olaparib, but, in most cases, it is mild[ 126 ].

Immune checkpoint inhibitors

The monoclonal antibodies known as checkpoint inhibitors (CPIs) target specific inhibitory receptors present in T cells, as well as in tumor cells and in other immune cells. The primary targets for checkpoint inhibition include programmed cell death 1 receptor (PD-1) and programmed cell death 1 ligand (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), that play an important role in negatively regulating T cell activation/function, thus tumor cells carrying PDL-1 or CTLA-4 are protected from immune reactions. The objective of checkpoint inhibitors is to restore or generate the activation of the immune system, directed to tumor cells[ 127 ].

Drugs targeting PD-1 (nivolumab and pembrolizumab) and PD-L1 (atezolizumab, avelumab, and durvalumab) have recently demonstrated their potential efficacy in different tumor types ( e.g ., urothelial carcinoma, non-small cell lung cancer, melanoma, head and neck cancer, Merkel cell carcinoma, renal cell carcinoma, Hodgkin lymphoma, and microsatellite instability-high or mismatch repair deficient [dMMR] solid tumors) and drugs targeting CTLA-4 (ipilimumab) is approved for use in patients with advanced melanoma[ 128 ].

The immune response generated by CPIs is complicated by a number of immune-related adverse events related to many different organs, including the kidneys[ 129 ]. AKI is a rare complication of checkpoint inhibitor immunotherapy, being mainly associated with ipilimumab/nivolumab combination therapy (4.9%)[ 130 ]. The most commonly reported underlying pathology is acute tubulointerstitial nephritis, but immune complex glomerulonephritis and TMA have also been observed[ 131 ]. There is also an association between CPIs treatment and electrolyte abnormalities, with hypocalcemia being the most significant. Discontinuation of checkpoint inhibitor immunotherapy and treatment with corticosteroids are indicated for patients with severe renal injury[ 132 ].

Other biologic agents

Interferon-alpha activates interleukin-2 (IL-2) release, which leads to cancer cell death[ 133 ]. Recombinant interferon-alpha can cause proteinuria, which can be in the nephrotic range and AKI, the histology is consistent with minimal change disease or focal segmental glomerulosclerosis[ 134 , 135 ]. Rarely, TMA is seen and in this situation prompt drug discontinuation is critical[ 136 ].

IL-2 is used for the management of metastatic renal cell carcinoma and metastatic melanoma. IL-2 therapy causes cytokine-driven capillary leak syndrome, leading to intravascular volume depletion, edema, and a reversible fall in GFR. In this context, AKI is a consequence of prerenal azotemia from capillary leak. It is important to highlight that ischemic acute tubular injury may also occur due to severe hypotension[ 137 ]. Cytokine-mediated inflammatory kidney injury may also occur[ 138 ].

Chemotherapy-induced nephron specific segment injury is shown in Figure 3 . The peptide receptor radioligand Lutetium Lu 177-dotatate is a radiolabeled somatostatin analog with potential antineoplastic activities. Lutetium Lu 177-dotatate binds to somatostatin receptors expressed by various neuroendocrine tumor cells. Once the radioligand binds to that receptor, this complex in internalized, resulting in beta radiation delivery to cells that express somatostatin receptors. Kidney irradiation may result in glomerular damage with renal impairment. An amino acid solution infusion is needed to protect the kidneys from the radiation effects of the therapeutic radionuclide. This protocol results in low rates of nephrotoxicity during therapy. No risk factors for renal toxicity have been identified[ 139 ].

CONCLUSION

Onco-nephrology has emerged as a new specialized therapeutic perspective for cancer patients. Despite the improvement of patients survival resulting from the use of conventional and molecularly targeted agents, several therapeutic complications due to nephrotoxic effects of these drugs have been reported. Given the background, it is important to know the possible adverse events related to these therapies, allowing early diagnosis of these effects, avoiding further issues due to this treatment. It is important to highlight that the approach in patients affected by nephrotoxicity due to anti-cancer drugs include, in addition to the forms previously mentioned specifically for each drug, close monitoring, proper hydration and dose reduction, with suspension of the agent use if necessary. It is also important to conduct more controlled studies in the sense of creating guidelines for dose adjustment in patients with renal impairment, since most of the dose adjustment standards for these drugs are being created recently through studies with small numbers of subjects and in initial stages of clinical trials. The development of these studies is also important to look at other treatment-associated nephrotoxic effects, as well as to reduce short and long-term complications related to such therapies.

Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

Manuscript source: Invited manuscript

Peer-review started: December 29, 2019

First decision: January 19, 2020

Article in press: March 22, 2020

Specialty type: Oncology

Country/Territory of origin: Brazil

Peer-review report´s scientific quality classification

Grade A (Excellent):

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor):

P-Reviewer: Manenti A, Tanabe S, Sridharan G S-Editor: Zhang L L-Editor: Filipodia E-Editor: Liu MY

1 Rosner MH Perazella MA Acute Kidney Injury in Patients with Cancer N Engl J Med 2017 376 1770 1781 28467867 10.1056/NEJMra1613984

2 Perazella MA Onco-nephrology: renal toxicities of chemotherapeutic agents Clin J Am Soc Nephrol 2012 7 1713 1721 22879440 10.2215/CJN.02780312

3 Perazella MA Izzedine H New drug toxicities in the onco-nephrology world Kidney Int 2015 87 909 917 25671763 10.1038/ki.2015.30

4 Jhaveri KD Fishbane S Nephrology Crossword: Onco-nephrology--chemotherapy agents and nephrotoxicity Kidney Int 2013 84 421 422

5 Owen JS Melhem M Passarell JA D'Andrea D Darwish M Kahl B Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma Cancer Chemother Pharmacol 2010 66 1039 1049 20140617 10.1007/s00280-010-1254-8 PMC2956859

6 Prediletto I Farag SA Bacher U Jeker B Mansouri Taleghani B Brégy R Zander T Betticher D Egger T Novak U Pabst T High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients Bone Marrow Transplant 2019 54 1923 1925 30890768 10.1038/s41409-019-0508-2

7 Ponticelli C Escoli R Moroni G Does cyclophosphamide still play a role in glomerular diseases? Autoimmun Rev 2018 17 1022 1027 30107267 10.1016/j.autrev.2018.04.007

8 Lim SR Hyun SH Lee SG Kim JY Kim SH Park SJ Moon KS Sul D Kim DH Choi HK Potential urinary biomarkers of nephrotoxicity in cyclophosphamide-treated rats investigated by NMR-based metabolic profiling J Biochem Mol Toxicol 2017 31 10.1002/jbt.21871 27870266

9 Bhat N Kalthur SG Padmashali S Monappa V Toxic Effects of Different Doses of Cyclophosphamide on Liver and Kidney Tissue in Swiss Albino Mice: A Histopathological Study Ethiop J Health Sci 2018 28 711 716 30607087 10.4314/ejhs.v28i6.5 PMC6308750

10 Liamis G Filippatos TD Elisaf MS Electrolyte disorders associated with the use of anticancer drugs Eur J Pharmacol 2016 777 78 87 26939882 10.1016/j.ejphar.2016.02.064

11 Ensergueix G Karras A [Ifosphamide nephrotoxicity] Nephrol Ther 2018 14 Suppl 1 S125 S131 29606257 10.1016/j.nephro.2018.02.008

12 Farry JK Flombaum CD Latcha S Long term renal toxicity of ifosfamide in adult patients--5 year data Eur J Cancer 2012 48 1326 1331 22503397 10.1016/j.ejca.2012.03.009

13 Falco P Bringhen S Avonto I Gay F Morabito F Boccadoro M Palumbo A Melphalan and its role in the management of patients with multiple myeloma Expert Rev Anticancer Ther 2007 7 945 957 17627453 10.1586/14737140.7.7.945

14 Greenbaum-Lefkoe B Rosenstock JG Belasco JB Rohrbaugh TM Meadows AT Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan Cancer 1985 55 44 46 3965085 10.1002/1097-0142(19850101)55:1<44::aid-cncr2820550107>3.0.co;2-b

15 Narins RG Carley M Bloom EJ Harrison DS The nephrotoxicity of chemotherapeutic agents Semin Nephrol 1990 10 556 564 2255813

16 Graham ML Janecek JL Kittredge JA Hering BJ Schuurman HJ The streptozotocin-induced diabetic nude mouse model: differences between animals from different sources Comp Med 2011 61 356 360 22330251 PMC3155402

17 Malyszko J Kozlowska K Kozlowski L Malyszko J Nephrotoxicity of anticancer treatment Nephrol Dial Transplant 2017 32 924 936 28339935 10.1093/ndt/gfw338

18 Pick AM Nystrom KK Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma J Oncol Pharm Pract 2010 16 269 272 20015930 10.1177/1078155209352821

19 Skorupa A Beldner M Kraft A Montero AJ Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma Cancer Biol Ther 2007 6 1015 1017 17611408 10.4161/cbt.6.7.4338

20 Kintzel PE Visser JA Campbell AD Clofarabine-associated acute kidney injury and proteinuria Pharmacotherapy 2011 31 923 21923594 10.1592/phco.31.9.923

21 Jhaveri KD Chidella S Allen SL Fishbane S Clofarabine-induced kidney toxicity J Oncol Pharm Pract 2014 20 305 308 24081220 10.1177/1078155213504976

22 van Besien K Stock W Rich E Odenike O Godley LA O'Donnell PH Kline J Nguyen V Del Cerro P Larson RA Artz AS Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 2012 18 913 921 22079470 10.1016/j.bbmt.2011.10.041 PMC3423318

23 Petri CR O'Donnell PH Cao H Artz AS Stock W Wickrema A Hard M van Besien K Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant Leuk Lymphoma 2014 55 2866 2873 24564572 10.3109/10428194.2014.897701 PMC4477686

24 Widemann BC Adamson PC Understanding and managing methotrexate nephrotoxicity Oncologist 2006 11 694 703 16794248 10.1634/theoncologist.11-6-694

25 Howell SB Carmody J Changes in glomerular filtration rate associated with high-dose methotrexate therapy in adults Cancer Treat Rep 1977 61 1389 1391 303938

26 Zattera T Londrino F Trezzi M Palumbo R Granata A Tatangelo P Corbani V Falqui V Chiappini N Mathiasen L Cavallini M Rolla D Pemetrexed-induced acute kidney failure following irreversible renal damage: two case reports and literature review J Nephropathol 2017 6 43 48 28491851 10.15171/jnp.2017.07 PMC5418068

27 Vootukuru V Liew YP Nally JV Jr Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer Med Oncol 2006 23 419 422 17018900 10.1385/MO:23:3:419

28 Stavroulopoulos A Nakopoulou L Xydakis AM Aresti V Nikolakopoulou A Klouvas G Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed Ren Fail 2010 32 1000 1004 20722569 10.3109/0886022X.2010.501930

29 Glezerman I Kris MG Miller V Seshan S Flombaum CD Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution Clin Nephrol 2009 71 130 139 19203505 10.5414/cnp71130

30 Iwasaki T Ohara H Matsumoto S Matsudaira H Test of magnetic sensitivity in three different biological systems J Radiat Res 1978 19 287 294 750665 10.1269/jrr.19.287

31 Rabah SO Acute Taxol nephrotoxicity: Histological and ultrastructural studies of mice kidney parenchyma Saudi J Biol Sci 2010 17 105 114 23961065 10.1016/j.sjbs.2010.02.003 PMC3730725

32 Garrett CA Simpson TA Jr Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy Ann Pharmacother 1998 32 1306 1309 9876812 10.1345/aph.17278

33 Cutting HO Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy Am J Med 1971 51 269 271 5095530 10.1016/0002-9343(71)90244-0

34 Carron PL Padilla M Maurizi Balzan J Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment Hemodial Int 2014 18 846 847 25040096 10.1111/hdi.12196

35 Shavit L Lifschitz MD Gabizon A Kwa M Muggia F Slotki I Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer Kidney Int 2014 85 213 10.1038/ki.2013.408 24380911

36 Groff JA Kozak M Boehmer JP Demko TM Diamond JR Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy Am J Kidney Dis 1997 29 280 284 9016902 10.1016/s0272-6386(97)90042-1

37 Cordonnier D Vert-Pré FC Bayle F Alix JL Couderc P [Nephrotoxicity of mitomycin C (apropos of 25 case reports). Results of a multicenter survey organized by the Society of Nephrology] Nephrologie 1985 6 19 26 3923381

38 Giroux L Bettez P Giroux L Mitomycin-C nephrotoxicity: a clinico-pathologic study of 17 cases Am J Kidney Dis 1985 6 28 39 3927715 10.1016/s0272-6386(85)80035-4

39 Bitran JD Desser RK Billings AA Kozloff MF Shapiro CM Acute nephrotoxicity following cis-dichlorodiammine-platinum Cancer 1982 49 1784 1788 7200396 10.1002/1097-0142(19820501)49:9<1784::aid-cncr2820490909>3.0.co;2-6

40 Crona DJ Faso A Nishijima TF McGraw KA Galsky MD Milowsky MI A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity Oncologist 2017 22 609 619 28438887 10.1634/theoncologist.2016-0319 PMC5423518

41 Raj GV Iasonos A Herr H Donat SM Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer J Clin Oncol 2006 24 3095 3100 16809735 10.1200/JCO.2005.04.3091

42 Kintzel PE Dorr RT Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function Cancer Treat Rev 1995 21 33 64 7859226 10.1016/0305-7372(95)90010-1

43 Joel SP Shah R Clark PI Slevin ML Predicting etoposide toxicity: relationship to organ function and protein binding J Clin Oncol 1996 14 257 267 8558207 10.1200/JCO.1996.14.1.257

44 Ries F Klastersky J Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity Am J Kidney Dis 1986 8 368 379 3538860 10.1016/s0272-6386(86)80112-3

45 McDonald BR Kirmani S Vasquez M Mehta RL Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature Am J Med 1991 90 386 391 2003521

46 Labaye J Sarret D Duvic C Hérody M Didelot F Nédélec G Noël LH Renal toxicity of oxaliplatin Nephrol Dial Transplant 2005 20 1275 1276 15827046 10.1093/ndt/gfh826

47 Takimoto CH Remick SC Sharma S Mani S Ramanathan RK Doroshow J Hamilton A Mulkerin D Graham M Lockwood GF Ivy P Egorin M Schuler B Greenslade D Goetz A Knight R Thomas R Monahan BP Dahut W Grem JL National Cancer Institute Organ Dysfunction Working Group Study Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study J Clin Oncol 2003 21 2664 2672 12860942 10.1200/JCO.2003.11.015

48 Robles-Osorio ML Sabath-Silva E Sabath E Arsenic-mediated nephrotoxicity Ren Fail 2015 37 542 547 25703706 10.3109/0886022X.2015.1013419

49 Sweeney CJ Takimoto C Wood L Porter JM Tracewell WG Darwish M D'Andrea DM Remick SC A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment Cancer Chemother Pharmacol 2010 66 345 356 19911123 10.1007/s00280-009-1169-4

50 Bennett WM Aronoff GR Morrison G Golper TA Pulliam J Wolfson M Singer I Drug prescribing in renal failure: dosing guidelines for adults Am J Kidney Dis 1983 3 155 193 6356890 10.1016/s0272-6386(83)80060-2

51 Slatter JG Schaaf LJ Sams JP Feenstra KL Johnson MG Bombardt PA Cathcart KS Verburg MT Pearson LK Compton LD Miller LL Baker DS Pesheck CV Lord RS 3rd Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients Drug Metab Dispos 2000 28 423 433 10725311

52 Ashizawa T Iwahori T Yokoyama T Kihara Y Konnno O Jyojima Y Akashi I Nakamura Y Hama K Iwamoto H Segawa M Takeuchi H Hirano T Nagao T Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer Acta Med Okayama 2010 64 19 26 20200580 10.18926/AMO/32861

53 O'Reilly S Rowinsky EK Slichenmyer W Donehower RC Forastiere AA Ettinger DS Chen TL Sartorius S Grochow LB Phase I and pharmacologic study of topotecan in patients with impaired renal function J Clin Oncol 1996 14 3062 3073 8955651 10.1200/JCO.1996.14.12.3062

54 Harris E Behrens J Samson D Rahemtulla A Russell NH Byrne JL Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia Br J Haematol 2003 122 160 161 12823359 10.1046/j.1365-2141.2003.04395_2.x

55 Fakhouri F Guerraoui H Presne C Peltier J Delarue R Muret P Knebelmann B Thalidomide in patients with multiple myeloma and renal failure Br J Haematol 2004 125 96 97 15015981 10.1111/j.1365-2141.2004.04875.x

56 Niesvizky R Naib T Christos PJ Jayabalan D Furst JR Jalbrzikowski J Zafar F Mark T Lent R Pearse RN Ely S Leonard JP Mazumdar M Chen-Kiang S Coleman M Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy Br J Haematol 2007 138 640 643 17686058 10.1111/j.1365-2141.2007.06698.x

57 Dimopoulos M Alegre A Stadtmauer EA Goldschmidt H Zonder JA de Castro CM Masliak Z Reece D Olesnyckyj M Yu Z Weber DM The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function Cancer 2010 116 3807 3814 20564094 10.1002/cncr.25139 PMC2970911

58 Lipson EJ Huff CA Holanda DG McDevitt MA Fine DM Lenalidomide-induced acute interstitial nephritis Oncologist 2010 15 961 964 20709889 10.1634/theoncologist.2010-0070 PMC3228035

59 Batts ED Sanchorawala V Hegerfeldt Y Lazarus HM Azotemia associated with use of lenalidomide in plasma cell dyscrasias Leuk Lymphoma 2008 49 1108 1115 18452093 10.1080/10428190802023707

60 Specter R Sanchorawala V Seldin DC Shelton A Fennessey S Finn KT Zeldis JB Dember LM Kidney dysfunction during lenalidomide treatment for AL amyloidosis Nephrol Dial Transplant 2011 26 881 886 20693160 10.1093/ndt/gfq482 PMC3108346

61 Richardson PG Siegel DS Vij R Hofmeister CC Baz R Jagannath S Chen C Lonial S Jakubowiak A Bahlis N Song K Belch A Raje N Shustik C Lentzsch S Lacy M Mikhael J Matous J Vesole D Chen M Zaki MH Jacques C Yu Z Anderson KC Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study Blood 2014 123 1826 1832 24421329 10.1182/blood-2013-11-538835 PMC3962162

62 Baird P Leung S Hoang H Babalola O Devoe CE Wanchoo R Jhaveri KD A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use J Oncol Pharm Pract 2016 22 357 360 25591868 10.1177/1078155214568581

63 Cheungpasitporn W Leung N Rajkumar SV Cornell LD Sethi S Angioi A Fervenza FC Bortezomib-induced acute interstitial nephritis Nephrol Dial Transplant 2015 30 1225 1229 26109684 10.1093/ndt/gfv222

64 Siegel DS Martin T Wang M Vij R Jakubowiak AJ Lonial S Trudel S Kukreti V Bahlis N Alsina M Chanan-Khan A Buadi F Reu FJ Somlo G Zonder J Song K Stewart AK Stadtmauer E Kunkel L Wear S Wong AF Orlowski RZ Jagannath S A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 2012 120 2817 2825 22833546 10.1182/blood-2012-05-425934 PMC4123387

65 Hájek R Masszi T Petrucci MT Palumbo A Rosiñol L Nagler A Yong KL Oriol A Minarik J Pour L Dimopoulos MA Maisnar V Rossi D Kasparu H Van Droogenbroeck J Yehuda DB Hardan I Jenner M Calbecka M Dávid M de la Rubia J Drach J Gasztonyi Z Górnik S Leleu X Munder M Offidani M Zojer N Rajangam K Chang YL San-Miguel JF Ludwig H A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) Leukemia 2017 31 107 114 27416912 10.1038/leu.2016.176 PMC5220126

66 Jhaveri KD Chidella S Varghese J Mailloux L Devoe C Carfilzomib-related acute kidney injury Clin Adv Hematol Oncol 2013 11 604 605 24518527

67 Liberman V D'Agati VD Masani NN Drakakis J Mattana J Acute Tubular Necrosis in a Patient With Myeloma Treated With Carfilzomib Kidney Int Rep 2016 1 89 92 29142917 10.1016/j.ekir.2016.06.002 PMC5678606

68 Yui JC Dispenzieri A Leung N Ixazomib-induced thrombotic microangiopathy Am J Hematol 2017 92 E53 E55 28133842 10.1002/ajh.24662

69 Singh D Attri BK Gill RK Bariwal J Review on EGFR Inhibitors: Critical Updates Mini Rev Med Chem 2016 16 1134 1166 26996617 10.2174/1389557516666160321114917

70 Gelatti ACZ Drilon A Santini FC Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) Lung Cancer 2019 137 113 122 31568888 10.1016/j.lungcan.2019.09.017 PMC7478849

71 Khan K Valeri N Dearman C Rao S Watkins D Starling N Chau I Cunningham D Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution Crit Rev Oncol Hematol 2019 143 153 163 31678702 10.1016/j.critrevonc.2019.09.001

72 Kumasaka R Nakamura N Shirato K Osawa H Takanashi S Hasegawa Y Yamabe H Nakamura M Tamura M Okumura K Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy J Clin Oncol 2004 22 2504 2505 15197213 10.1200/JCO.2004.09.064

73 Maruyama K Chinda J Kuroshima T Kabara M Nakagawa N Fujino T Yamamoto Y Ohsaki Y Ogawa Y Hasebe N Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib Intern Med 2015 54 823 826 25832950 10.2169/internalmedicine.54.3661

74 Kaneko T Shimizu A Aoki M Tsuruoka S A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma CEN Case Rep 2015 4 31 37 28509266 10.1007/s13730-014-0135-0 PMC5413710

75 Jhaveri KD Sakhiya V Wanchoo R Ross D Fishbane S Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System Kidney Int 2016 90 706 707 27521117 10.1016/j.kint.2016.06.027

76 Schrag D Chung KY Flombaum C Saltz L Cetuximab therapy and symptomatic hypomagnesemia J Natl Cancer Inst 2005 97 1221 1224 16106027 10.1093/jnci/dji242

77 Tejpar S Piessevaux H Claes K Piront P Hoenderop JG Verslype C Van Cutsem E Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study Lancet Oncol 2007 8 387 394 17466895 10.1016/S1470-2045(07)70108-0

78 Cao Y Liu L Liao C Tan A Gao F Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer Cancer Chemother Pharmacol 2010 66 37 42 19760217 10.1007/s00280-009-1131-5

79 Harari PM Epidermal growth factor receptor inhibition strategies in oncology Endocr Relat Cancer 2004 11 689 708 15613446 10.1677/erc.1.00600

80 Nagaraja V Shaw N Morey AL Cox MR Eslick GD HER2 expression in oesophageal carcinoma and Barrett's oesophagus associated adenocarcinoma: An Australian study Eur J Surg Oncol 2016 42 140 148 26422587 10.1016/j.ejso.2015.08.159

81 Gowryshankar A Nagaraja V Eslick GD HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis J Gastrointest Oncol 2014 5 25 35 24490040 10.3978/j.issn.2078-6891.2013.039 PMC3904023

82 Burstein HJ The distinctive nature of HER2-positive breast cancers N Engl J Med 2005 353 1652 1654 16236735 10.1056/NEJMp058197

83 Albanell J Baselga J Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer Drugs Today (Barc) 1999 35 931 946 12973420

84 de Souza JA Davis DW Zhang Y Khattri A Seiwert TY Aktolga S Wong SJ Kozloff MF Nattam S Lingen MW Kunnavakkam R Stenson KM Blair EA Bozeman J Dancey JE Vokes EE Cohen EE A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck Clin Cancer Res 2012 18 2336 2343 22371453 10.1158/1078-0432.CCR-11-2825 PMC4467891

85 Ryan CE Davids MS BCL-2 Inhibitors, Present and Future Cancer J 2019 25 401 409 31764121 10.1097/PPO.0000000000000408

86 Wanchoo R Bernabe Ramirez C Barrientos J Jhaveri KD Renal involvement in chronic lymphocytic leukemia Clin Kidney J 2018 11 670 680 30288263 10.1093/ckj/sfy026 PMC6165759

87 Cheson BD Heitner Enschede S Cerri E Desai M Potluri J Lamanna N Tam C Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents Oncologist 2017 22 1283 1291 28851760 10.1634/theoncologist.2017-0055 PMC5679833

88 Ladanyi M Cavalchire G Morris SW Downing J Filippa DA Reverse transcriptase polymerase chain reaction for the Ki-1 anaplastic large cell lymphoma-associated t(2;5) translocation in Hodgkin's disease Am J Pathol 1994 145 1296 1300 7527617 PMC1887484

89 Orscheschek K Merz H Hell J Binder T Bartels H Feller AC Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin's disease: indication of a common pathogenesis? Lancet 1995 345 87 90 7815887 10.1016/s0140-6736(95)90061-6

90 Pillay K Govender D Chetty R ALK protein expression in rhabdomyosarcomas Histopathology 2002 41 461 467 12405914 10.1046/j.1365-2559.2002.01534.x

91 Chen Y Takita J Choi YL Kato M Ohira M Sanada M Wang L Soda M Kikuchi A Igarashi T Nakagawara A Hayashi Y Mano H Ogawa S Oncogenic mutations of ALK kinase in neuroblastoma Nature 2008 455 971 974 18923524 10.1038/nature07399

92 Shinmura K Kageyama S Tao H Bunai T Suzuki M Kamo T Takamochi K Suzuki K Tanahashi M Niwa H Ogawa H Sugimura H EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas Lung Cancer 2008 61 163 169 18242762 10.1016/j.lungcan.2007.12.013

93 Camidge DR Brosnan EM DeSilva C Koo PJ Chonchol M Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate J Thorac Oncol 2014 9 1634 1637 25436798 10.1097/JTO.0000000000000321

94 Lin YT Wang YF Yang JC Yu CJ Wu SG Shih JY Yang PC Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer J Thorac Oncol 2014 9 1720 1725 25436806 10.1097/JTO.0000000000000326

95 Izzedine H El-Fekih RK Perazella MA The renal effects of ALK inhibitors Invest New Drugs 2016 34 643 649 27468827 10.1007/s10637-016-0379-y

96 Hauschild A Grob JJ Demidov LV Jouary T Gutzmer R Millward M Rutkowski P Blank CU Miller WH Jr Kaempgen E Martín-Algarra S Karaszewska B Mauch C Chiarion-Sileni V Martin AM Swann S Haney P Mirakhur B Guckert ME Goodman V Chapman PB Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 2012 380 358 365 22735384 10.1016/S0140-6736(12)60868-X

97 Chapman PB Hauschild A Robert C Haanen JB Ascierto P Larkin J Dummer R Garbe C Testori A Maio M Hogg D Lorigan P Lebbe C Jouary T Schadendorf D Ribas A O'Day SJ Sosman JA Kirkwood JM Eggermont AM Dreno B Nolop K Li J Nelson B Hou J Lee RJ Flaherty KT McArthur GA BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 2011 364 2507 2516 21639808 10.1056/NEJMoa1103782 PMC3549296

98 Hurabielle C Pillebout E Stehlé T Pagès C Roux J Schneider P Chevret S Chaffaut C Boutten A Mourah S Basset-Seguin N Vidal-Petiot E Lebbé C Flamant M Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma PLoS One 2016 11 e0149873 26930506 10.1371/journal.pone.0149873 PMC4773169

99 Jhaveri KD Sakhiya V Fishbane S Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib JAMA Oncol 2015 1 1133 1134 26182194 10.1001/jamaoncol.2015.1713

100 Temsirolimus 2012, In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–2013 Dec 10 31643176

101 Izzedine H Escudier B Rouvier P Gueutin V Varga A Bahleda R Soria JC Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven Ann Oncol 2013 24 2421 2425 23798615 10.1093/annonc/mdt233

102 Rowley JD Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 1973 243 290 293 4126434 10.1038/243290a0

103 Vogelstein B Kinzler KW The multistep nature of cancer Trends Genet 1993 9 138 141 8516849 10.1016/0168-9525(93)90209-z

104 Cortes JE Gambacorti-Passerini C Kim DW Kantarjian HM Lipton JH Lahoti A Talpaz M Matczak E Barry E Leip E Brümmendorf TH Khoury HJ Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias Clin Lymphoma Myeloma Leuk 2017 17 684 695.e6 28807791 10.1016/j.clml.2017.06.001

105 Ozkurt S Temiz G Acikalin MF Soydan M Acute renal failure under dasatinib therapy Ren Fail 2010 32 147 149 20113282 10.3109/08860220903391226

106 Calizo RC Bhattacharya S van Hasselt JGC Wei C Wong JS Wiener RJ Ge X Wong NJ Lee JJ Cuttitta CM Jayaraman G Au VH Janssen W Liu T Li H Salem F Jaimes EA Murphy B Campbell KN Azeloglu EU Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity Nat Commun 2019 10 2061 31053734 10.1038/s41467-019-09936-x PMC6499885

107 Marcolino MS Boersma E Clementino NC Macedo AV Marx-Neto AD Silva MH van Gelder T Akkerhuis KM Ribeiro AL Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients Ann Oncol 2011 22 2073 2079 21310760 10.1093/annonc/mdq715

108 Pou M Saval N Vera M Saurina A Solé M Cervantes F Botey A Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia Leuk Lymphoma 2003 44 1239 1241 12916879 10.1080/1042819031000079140

109 Berman E Nicolaides M Maki RG Fleisher M Chanel S Scheu K Wilson BA Heller G Sauter NP Altered bone and mineral metabolism in patients receiving imatinib mesylate N Engl J Med 2006 354 2006 2013 16687713 10.1056/NEJMoa051140

110 Ferrara N VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2002 2 795 803 12360282 10.1038/nrc909

111 Launay-Vacher V Aapro M De Castro G Jr Cohen E Deray G Dooley M Humphreys B Lichtman S Rey J Scotté F Wildiers H Sprangers B Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN) Ann Oncol 2015 26 1677 1684 25735315 10.1093/annonc/mdv136

112 Eremina V Jefferson JA Kowalewska J Hochster H Haas M Weisstuch J Richardson C Kopp JB Kabir MG Backx PH Gerber HP Ferrara N Barisoni L Alpers CE Quaggin SE VEGF inhibition and renal thrombotic microangiopathy N Engl J Med 2008 358 1129 1136 18337603 10.1056/NEJMoa0707330 PMC3030578

113 Launay-Vacher V Deray G Hypertension and proteinuria: a class-effect of antiangiogenic therapies Anticancer Drugs 2009 20 81 82 19343005 10.1097/CAD.0b013e3283161012

114 Tomita Y Uemura H Fujimoto H Kanayama HO Shinohara N Nakazawa H Imai K Umeyama Y Ozono S Naito S Akaza H Japan Axitinib Phase II Study Group Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma Eur J Cancer 2011 47 2592 2602 21889330 10.1016/j.ejca.2011.07.014

115 Shord SS Bressler LR Tierney LA Cuellar S George A Understanding and managing the possible adverse effects associated with bevacizumab Am J Health Syst Pharm 2009 66 999 1013 19451611 10.2146/ajhp080455

116 Patel TV Morgan JA Demetri GD George S Maki RG Quigley M Humphreys BD A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib J Natl Cancer Inst 2008 100 282 284 18270341 10.1093/jnci/djm311

117 Van Cutsem E Tabernero J Lakomy R Prenen H Prausová J Macarulla T Ruff P van Hazel GA Moiseyenko V Ferry D McKendrick J Polikoff J Tellier A Castan R Allegra C Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 2012 30 3499 3506 22949147 10.1200/JCO.2012.42.8201

118 Shord SS Bressler LR Tierney LA Cuellar S George A Understanding and managing the possible adverse effects associated with bevacizumab Am J Health Syst Pharm 2009 66 999 1013 19451611 10.2146/ajhp080455

119 Gurevich F Perazella MA Renal effects of anti-angiogenesis therapy: update for the internist Am J Med 2009 122 322 328 19332223 10.1016/j.amjmed.2008.11.025

120 Grothey A Van Cutsem E Sobrero A Siena S Falcone A Ychou M Humblet Y Bouché O Mineur L Barone C Adenis A Tabernero J Yoshino T Lenz HJ Goldberg RM Sargent DJ Cihon F Cupit L Wagner A Laurent D CORRECT Study Group Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 2013 381 303 312 23177514 10.1016/S0140-6736(12)61900-X

121 Winn SK Ellis S Savage P Sampson S Marsh JE Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 2009 24 673 675 19039026 10.1093/ndt/gfn625

122 Izzedine H Brocheriou I Rixe O Deray G Interstitial nephritis in a patient taking sorafenib Nephrol Dial Transplant 2007 22 2411 17470456 10.1093/ndt/gfm199

123 Escudier B Eisen T Stadler WM Szczylik C Oudard S Siebels M Negrier S Chevreau C Solska E Desai AA Rolland F Demkow T Hutson TE Gore M Freeman S Schwartz B Shan M Simantov R Bukowski RM TARGET Study Group Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 2007 356 125 134 17215530 10.1056/NEJMoa060655

124 Chanan-Khan A Cramer P Demirkan F Fraser G Silva RS Grosicki S Pristupa A Janssens A Mayer J Bartlett NL Dilhuydy MS Pylypenko H Loscertales J Avigdor A Rule S Villa D Samoilova O Panagiotidis P Goy A Mato A Pavlovsky MA Karlsson C Mahler M Salman M Sun S Phelps C Balasubramanian S Howes A Hallek M HELIOS investigators Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study Lancet Oncol 2016 17 200 211 26655421 10.1016/S1470-2045(15)00465-9

125 Kreitman RJ Dearden C Zinzani PL Delgado J Karlin L Robak T Gladstone DE le Coutre P Dietrich S Gotic M Larratt L Offner F Schiller G Swords R Bacon L Bocchia M Bouabdallah K Breems DA Cortelezzi A Dinner S Doubek M Gjertsen BT Gobbi M Hellmann A Lepretre S Maloisel F Ravandi F Rousselot P Rummel M Siddiqi T Tadmor T Troussard X Yi CA Saglio G Roboz GJ Balic K Standifer N He P Marshall S Wilson W Pastan I Yao NS Giles F Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia Leukemia 2018 32 1768 1777 30030507 10.1038/s41375-018-0210-1 PMC6087717

126 Dean E Middleton MR Pwint T Swaisland H Carmichael J Goodege-Kunwar P Ranson M Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours Br J Cancer 2012 106 468 474 22223088 10.1038/bjc.2011.555 PMC3273358

127 Weber J Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade Semin Oncol 2010 37 430 439 21074057 10.1053/j.seminoncol.2010.09.005

128 Food and Drug Administration Pembrolizumab (KEYTRUDA), checkpoint inhibitor. [published 2016 October 25 Oct; cited 2019 December 16] Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda-checkpoint-inhibitor

129 Champiat S Lambotte O Barreau E Belkhir R Berdelou A Carbonnel F Cauquil C Chanson P Collins M Durrbach A Ederhy S Feuillet S François H Lazarovici J Le Pavec J De Martin E Mateus C Michot JM Samuel D Soria JC Robert C Eggermont A Marabelle A Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper Ann Oncol 2016 27 559 574 26715621 10.1093/annonc/mdv623

130 Cortazar FB Marrone KA Troxell ML Ralto KM Hoenig MP Brahmer JR Le DT Lipson EJ Glezerman IG Wolchok J Cornell LD Feldman P Stokes MB Zapata SA Hodi FS Ott PA Yamashita M Leaf DE Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors Kidney Int 2016 90 638 647 27282937 10.1016/j.kint.2016.04.008 PMC4983464

131 Mamlouk O Selamet U Machado S Abdelrahim M Glass WF Tchakarov A Gaber L Lahoti A Workeneh B Chen S Lin J Abdel-Wahab N Tayar J Lu H Suarez-Almazor M Tannir N Yee C Diab A Abudayyeh A Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience J Immunother Cancer 2019 7 2 30612580 10.1186/s40425-018-0478-8 PMC6322290

132 Shirali AC Perazella MA Gettinger S Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients Am J Kidney Dis 2016 68 287 291 27113507 10.1053/j.ajkd.2016.02.057

133 Lesinski GB Anghelina M Zimmerer J Bakalakos T Badgwell B Parihar R Hu Y Becknell B Abood G Chaudhury AR Magro C Durbin J Carson WE 3rd The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse J Clin Invest 2003 112 170 180 12865406 10.1172/JCI16603 PMC164283

134 Markowitz GS Nasr SH Stokes MB D'Agati VD Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis Clin J Am Soc Nephrol 2010 5 607 615 20203164 10.2215/CJN.07311009 PMC2849683

135 Ozturk M Basoglu F Yilmaz M Ozagari AA Baybas S Interferon β associated nephropathy in a Multiple Sclerosis patient: A case and review Mult Scler Relat Disord 2016 9 50 53 27645343 10.1016/j.msard.2016.06.012

136 Zuber J Martinez F Droz D Oksenhendler E Legendre C Groupe D'stude Des Nephrologues D'ile-de-France (GENIF) Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature Medicine (Baltimore) 2002 81 321 331 12169887 10.1097/00005792-200207000-00008

137 Webb DE Austin HA 3rd Belldegrun A Vaughan E Linehan WM Rosenberg SA Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer Clin Nephrol 1988 30 141 145 3263237

138 Marabondo S Kaufman HL High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions Expert Opin Drug Saf 2017 16 1347 1357 28929820 10.1080/14740338.2017.1382472

139 Bergsma H Konijnenberg MW van der Zwan WA Kam BL Teunissen JJ Kooij PP Mauff KA Krenning EP Kwekkeboom DJ Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate Eur J Nucl Med Mol Imaging 2016 43 1802 1811 27160225 10.1007/s00259-016-3382-9 PMC4969358